Nathan Singh, MD, MS

Nathan Singh, MD, MS

Assistant Professor

Address:
Division of Oncology
Mail Stop 8007-0057-06
Washington University
660 South Euclid Avenue
St. Louis, MO 63110

Room 643 Southwest Tower (office)

Admin:
Shannon Dobbs
dobbss@wustl.edu

Clinical Interests
  • Cellular therapies for hematologic cancers
Research Interests
  • Engineered T cells
  • Synthetic protein biology
  • T cell development and dysfunction in the context of immunotherapy
Research

Nathan Singh is joining the faculty as an assistant professor on the investigator track in the Division of Oncology, Section of Stem Cell Biology. He comes to Wash U from the Univesity of Pennsylvania, where he completed a combined MD/Masters of Science in Translational research program, during which he spent two years in the laboratory of Dr. Stephan Grupp. After medical school, he did clinical training in internal medicine, hematology and oncology, with focused training in cellular therapy and the management of leukemia. Following clinical training, Nathan did his fellowship research with Dr. Carl June, studying mechanisms driving failure of chimeric antigen receptor (CAR) T cell therapies. As part of the Penn Center for Cellular Immunotherapies group for over 10 years, he has gained expertise in all aspects of cell therapy research and clinical practice.

Dr. Singh’s laboratory at Wash U will investigate how these novel receptors regulate T cell function and dysfunction. Despite promising early results, long-term follow-up has now revealed that nearly half of patients treated with CAR T cells for hematologic cancers will not experience long-term remissions. Using a variety of techniques in cell lines and primary patient samples, the Singh Lab aims to understand how interactions between engineered T cells and blood cancer cells in some cases lead to disease cure, and in others to therapeutic failure. The broad goals of the lab are to elucidate the biological principles governing the activity of these synthetic receptors and use these as a blueprint to design the next-generation of “intelligent” cellular therapies.

In addition to his research, Nathan will attend on the inpatient cellular therapy and hematopoietic cell transplantation service. As a physician-scientist focused on cellular therapies, Nathan is very interested in mentoring graduate and medical students, as well as post-doctoral and physician fellows in translational immunology and immunotherapy for cancer.

Biosketch

Education

  • 2013: MD, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
  • 2013: MS (Translational Research), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
  • 2006: BA (Biology and Spanish Literature), Haverford College, Haverford, PA

Post-Graduate Training

  • 2019-2016: Fellow, Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
  • 2016-2013: Resident, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

Academic Positions & Employment

  • present-2019: Assistant Professor of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO

Other Professional Positions

  • present-2022: Board of Directors, Phoreus Biotech

Board Certification

  • 2019: American Board of Internal Medicine, Subspecialty in Hematology
  • 2017: American Board of Internal Medicine

Honors & Awards

  • 2017: Molecular Biology in Clinical Oncology Workshop, American Association for Cancer Research
  • 2016: Above and Beyond Award, Housestaff and Nursing Quality Counsel, Hospital of the University of Pennsylvania
  • 2015: Austrian Award for Basic Science Research, Department of Medicine, University of Pennsylvania
  • 2013: Rose Meadow Levinson Memorial Prize for Meritorious Laboratory Research in the Field of Cancer, Perelman School of Medicine at the University of Pennsylvania
  • 2012: Presidential Travel Award, Society for Immunotherapy of Cancer
  • 2006: Honors Thesis, Haverford College Department of Biology, Haverford College Department of Spanish
  • 2006: Marian Koshland Award for Excellence in Biological Research, Haverford College Department of Biology
  • 2006: Outstanding Student Research Award, Sigma Xi Scientifics Honors Society
  • 2005: HHMI Interdisciplinary Science Scholar, Howard Hughes Medical Institute

National & International Grant Reviews

  • present-2020: Medical Research Council, United Kingdom
  • 2022: NIH/NCI, TTT Stucy Section (Ad Hoc Reviewer)
  • 2022: Society for Immunotherapy of Cancer Fellowship Program
  • 2022: European Research Council Synergy Program

Advisory Committees

  • 2022: University of North Carolina Lineberger Cancer Center Data Safety and Monitoring Committee Blue (Cellular Therapies) External Advisory Board

Professional Societies

  • present-2016: European Academy of Tumor Immunology
  • present-2016: American Association for the Advancement of Science
  • present-2015: American Society of Gene and Cell Therapy
  • present-2014: American Society of Clinical Oncology
  • present-2013: American Society of Hematology
  • present-2012: International Society for Cellular Therapy
  • present-2012: Society for Immunotherapy of Cancer
    • Science and Research Subcommittee, present-2021
  • present-2012: American Association for Cancer Research